<?xml version="1.0" encoding="UTF-8"?>
<ref id="R5">
 <label>5</label>
 <mixed-citation publication-type="journal">
  <person-group person-group-type="author">
   <name name-style="western">
    <surname>Al-Batran</surname>
    <given-names>S-E</given-names>
   </name>, 
   <name name-style="western">
    <surname>Hofheinz</surname>
    <given-names>RD</given-names>
   </name>, 
   <name name-style="western">
    <surname>Pauligk</surname>
    <given-names>C</given-names>
   </name>, 
   <etal>et al</etal>
  </person-group>
  <article-title>Histopathological regression after neoadjuvant docetaxel, oxaliplatin, fluorouracil, and leucovorin versus epirubicin, cisplatin, and fluorouracil or capecitabine in patients with resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4-AIO): results from the phase 2 part of a multicentre, open-label, randomised phase 2/3 trial</article-title>. 
  <source>Lancet Oncol</source>
  <year>2016</year>;
  <volume>17</volume>:
  <fpage>1697</fpage>â€“
  <lpage>708</lpage>. 
  <pub-id pub-id-type="doi">10.1016/S1470-2045(16)30531-9</pub-id>
  <?supplied-pmid http://www.ncbi.nlm.nih.gov/pubmed/27776843?>
  <pub-id pub-id-type="pmid">27776843</pub-id>
 </mixed-citation>
</ref>
